Clinical trials with oral Futraful (INN: Tegafur) in cancer of the head and neck.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009062:Mouth Neoplasms / Q000188:drug therapy; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D010844:Picibanil / Q000627:therapeutic use; D011509:Proteoglycans / Q000627:therapeutic use; D005641:Tegafur / Q000627:therapeutic use* / Q000633:toxicity
D000970:Antineoplastic Agents; D011509:Proteoglycans; D005641:Tegafur; D010844:Picibanil; C010770:polysaccharide-K; D005472:Fluorouracil